Patents Represented by Attorney Michael M. Conger
-
Patent number: 8263384Abstract: Novel organisms, including DNA construct host cell combinations, are disclosed. The organisms comprise a transcription unit (e.g. operon) comprising DNA sequences encoding for enzymes which promote the supply of single carbon units for the conversion of dUMP to dTMP. Examples include: dihydrofolate reductase genes e.g. T4 frd; Serine Hydroxymethyltransferase genes e.g. glyA; 3-phosphoglycerate dehydrogenase genes e.g. serA; and THF synthase genes e.g. ADE3. The organisms are used in a biological method of producing thymidine with significantly reduced levels of uridine.Type: GrantFiled: February 5, 2007Date of Patent: September 11, 2012Assignee: Glaxo Group LimitedInventors: David Martin Anderson, Andrew John Collis, Lin Liu, Sergey Podkovyrov, Christopher Preston
-
Patent number: 8221991Abstract: The present invention relates to a novel human orphan nuclear receptor that binds to a cytochrome P-450 monooxygenase (CYP) promoter and that is activated by compounds that induce CYP gene expression. The invention further relates to nucleic acid sequences encoding such a receptor, to methods of making the receptor and to methods of using the receptor and nucleic acid sequences encoding same. The invention also relates to non-human animals transformed to express the human receptor and to methods of using such animals to screen compounds for drug interactions and toxicities.Type: GrantFiled: September 8, 2010Date of Patent: July 17, 2012Assignee: GlaxoSmithKline LLCInventors: Steven A. Kliewer, Stacey A. Jones, Timothy M. Willson
-
Patent number: 8173411Abstract: The present invention relates to a method of drying biological and other labile samples so that they can be preserved as a highly viscous liquid. The method involves the steps of preparing a preservation sample by dissolving/suspending an active agent in a solution of a stabilizing agent, subjecting the preservation sample to such temperature and pressure conditions that the preservation sample looses solvent by evaporation without freezing or bubbling to form a foam and removing solvent until the preservation sample dries to form a highly viscous liquid. The stabilizing solution comprises a glass forming polyol and a second component which decreases the flow rate of the highly viscous liquid formed by the method.Type: GrantFiled: April 28, 2005Date of Patent: May 8, 2012Assignee: GlaxoSmithKline Biologicals S.A.Inventor: Yves Mayeresse
-
Patent number: 7927858Abstract: The present invention relates to a method of drying biological and other labile samples so that they can be preserved as a highly viscous liquid. The method involves the steps of preparing a preservation sample by dissolving/suspending an active agent in a solution of a stabilizing agent, subjecting the preservation sample to such temperature and pressure conditions that the preservation sample loses solvent by evaporation without freezing or bubbling to form a foam and removing solvent until the preservation sample dries to form a highly viscous liquid.Type: GrantFiled: October 30, 2003Date of Patent: April 19, 2011Assignee: GlaxoSmithKline Biologicals, S.A.Inventor: Yves Mayeresse
-
Patent number: 7648703Abstract: A combination of an anti-Ep-CAM antibody with a chemotherapeutic agent that is capable of arresting Ep-CAM antigen expressing cells in S or G2/M.Type: GrantFiled: January 13, 2005Date of Patent: January 19, 2010Assignee: GlaxoSmithKline LLCInventors: Vincent C. Knick, Julie Beth Stimmel, Linda M. Thurmond
-
Patent number: 7541020Abstract: Aminoalkyl glucosaminide phosphate (AGP) compounds that are adjuvants and immunoeffectors are described and claimed. The compounds have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compounds are phosphorylated at the 4 or 6 carbon on the glucosaminide ring and comprise three 3-alkanoyloxyalkanoyl residues. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compositions and methods for using the compounds as adjuvants and immunoeffectors are also disclosed.Type: GrantFiled: April 30, 2002Date of Patent: June 2, 2009Assignee: Corixa CorporationInventors: David A Johnson, C Gregory Sowell
-
Patent number: 7510698Abstract: The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent induces of a range of immune responses.Type: GrantFiled: January 12, 2007Date of Patent: March 31, 2009Assignee: GlaxoSmithKline Biologicals SAInventors: Patricia Marie Momin, Nathalie Marie-Josephe Garcon
-
Patent number: 7399472Abstract: The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.Type: GrantFiled: March 3, 2003Date of Patent: July 15, 2008Assignee: Smithkline Beecham BiologicalsInventors: Martin Friede, Nathalie Garcon, Catherine Marie Ghislaine Gerard, Philippe Hermand
-
Patent number: 7387893Abstract: Novel DNA constructs and host cells comprising the same are disclosed. DNA constructs comprise a transcription unit (e.g. operon) comprising DNA sequences encoding for ribonucleotide reductase and thioredoxin or a uridine kinase gene and/or a dCTP deaminase gene. In preferred embodiments the constructs comprising DNA sequences encoding for ribonucleotide reductase and thioredoxin further comprise DNA sequences encoding for thymidylate synthase and/or transcription units comprising sequences encoding for uridine kinase preferably together with dCTP deaminase. In particularly preferred embodiments, the host cells comprise constructs having all of the above characteristics wherein the host cell displays repressed or no uracil DNA glycosylase activity. This may be achieved by removal of the host cell ung gene. Use of host cells in the manufacture of pyrimidine deoxyribonucleotides e.g. thymidine is also disclosed.Type: GrantFiled: August 9, 2004Date of Patent: June 17, 2008Assignee: SmithKline Beecham CorporationInventors: David Martin Anderson, Lin Liu, Sergey Podkovyrov, Baomin Wang
-
Patent number: 7357936Abstract: The present invention provides vaccine and adjuvant formulation comprising an immunostimulant and a metal salt. The immunostimulant is adsorbed onto a particle of metal salt and the resulting particle is essentially devoid of antigen.Type: GrantFiled: October 8, 1999Date of Patent: April 15, 2008Assignee: SmithKline Beecham Biologicals, SAInventor: Nathalie Garcon
-
Method to improve translation of polypeptides by using untranslated regions from heat-shock proteins
Patent number: 7351818Abstract: Untranslated regions associated with the heat shock response can be used to obtain increased efficiency of translation of polypeptides that are not necessarily normally associated with the heat shock response. This allows the development of greatly improved expression systems. The invention is also useful, for example, in the treatment of a patient suffering from a deficiency in the expression of a polypeptide and in the provision of vaccines.Type: GrantFiled: June 27, 2005Date of Patent: April 1, 2008Assignee: SmithKline Beecham CorporationInventors: Herve Jean-Clement Coste, Jonathan Henry Ellis -
Patent number: 7323182Abstract: The present invention relates to an oil in water emulsion vaccine composition. In particular, the present invention relates to a vaccine adjuvant formulation based on oil in water emulsion comprising a metabolisable oil and a saponin, wherein the oil and a saponin are present in a ratio of between 1:1 and 200:1. The invention further relates to methods for preparing the emulsion and its use in medicine.Type: GrantFiled: May 6, 2002Date of Patent: January 29, 2008Assignee: Smithkline Beecham Biologicals SGInventors: Nathalie Garcon, Patricia Marie Christine Aline Francoise Momin
-
Patent number: 7238491Abstract: The present invention relates to a novel human orphan nuclear receptor that binds to a cytochrome P-450 monooxygenase (CYP) promoter and that is activated by compounds that induce CYP gene expression. The invention further relates to nucleic acid sequences encoding such a receptor, to methods of making the receptor and to methods of using the receptor and nucleic acid sequences encoding same. The invention also relates to non-human animals transformed to express the human receptor and to methods of using such animals to screen compounds for drug interactions and toxicities.Type: GrantFiled: March 26, 1999Date of Patent: July 3, 2007Assignee: SmithKline Beecham CorporationInventors: Steven A. Kliewer, Stacey A. Jones, Timothy M. Willson
-
Patent number: 7169391Abstract: The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent induces of a range of immune responses.Type: GrantFiled: August 10, 2005Date of Patent: January 30, 2007Assignee: Smithkline Beecham Biologicals (S.A.)Inventors: Patricia Marie Momin, Nathalie Marie-Josephe Garcon
-
Patent number: 7063967Abstract: Aminoalkyl glucosaminide phosphate (AGP) compounds that are adjuvants and immunoeffectors are described and claimed. The compounds have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl (aglycon) group. Compounds are phosphorylated at the 4 or 6 carbon on the glucosaminide ring and comprise three 3-alkanoyloxyalkanoyl residues. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compositions and methods for using the compounds as adjuvants and immunoeffectors are also disclosed.Type: GrantFiled: January 8, 2002Date of Patent: June 20, 2006Assignee: Corixa CorporationInventors: David A. Johnson, C. Gregory Sowell
-
Patent number: 7038105Abstract: The present invention provides a transgenic non-human animal and method for using the same in evaluating a therapeutic agent for use in the treatment of Schizophrenia. More specifically, the invention is directed to a transgenic non-human animal which is incapable of expressing functional EDG2 protein. A theraupeutic agent is administered to the transgenic non-human animal incapable of expressing functional EDG2 protein and the effect of the agent on the animal is evaluated.Type: GrantFiled: August 22, 2002Date of Patent: May 2, 2006Assignee: Smithkline Beecham CorporationInventors: Peter Ronald Maycox, Charles Alan Reavill
-
Method to improve translation of polypeptides by using untranslated regions from heat-shock proteins
Patent number: 7034142Abstract: Untranslated regions associated with the heat shock response can be used to obtain increased efficiency of translation of polypeptides that are not necessarily normally associated with the heat shock response. This allows the development of greatly improved expression systems. The invention is also useful, for example, in the treatment of a patient suffering from a deficiency in the expression of a polypeptide and in the provision of vaccines.Type: GrantFiled: March 9, 2000Date of Patent: April 25, 2006Assignee: SmithKline Beecham CorporationInventors: Herve Jean-Clement Coste, Jonathan Henry Ellis -
Patent number: 7029678Abstract: The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent induces of a range of immune responses.Type: GrantFiled: September 3, 2003Date of Patent: April 18, 2006Assignee: SmithKline Beecham Biologicals (S.A.)Inventors: Patricia Marie Momin, Nathalie Marie-Josephe Garcon
-
Patent number: 6983753Abstract: The present invention relates, in general, to thermography and, in particular, to a method of using infrared thermography to monitor physiological and molecular events that elicit a thermogenic response in animals (including humans), plants, tissues, cells and cell-free systems. The present method can be used for screening, identifying, and ranking drug candidates for multiple diseases, disorders and conditions.Type: GrantFiled: November 17, 2000Date of Patent: January 10, 2006Assignee: SmithKline Beecham CorporationInventors: James Martin Lenhard, Mark Andrew Paulik
-
Patent number: 6881584Abstract: The present invention relates, in general, to thermography and, in particular, to a method of using infrared thermography to monitor physiological and molecular events that elicit a thermogenic response in animals (including humans), plants, tissues, cells and cell-free systems. The present method can be used for screening, identifying, and ranking drug candidates for multiple diseases, disorders and conditions.Type: GrantFiled: November 17, 1999Date of Patent: April 19, 2005Assignee: SmithKline Beecham CorporationInventors: James Martin Lenhard, Mark Andrew Paulik